IDE-892 / Ideaya Biosci - LARVOL DELTA

IDE892 monotherapy and combination with IDE397 in methylthioadenosine phosphorylase-deleted (MTAPdel) advanced solid tumors (IDE892-001) (ESMO 2026) - No abstract available

Metastases • Monotherapy • Oncology • Solid Tumor • MTAP

IDEAYA entered into a clinical collaboration to evaluate IDE892, IDEAYA's potential best-in-class Phase 1 MTA-cooperative PRMT5 inhibitor, in combination with RG6620, Genentech's Phase 1 KRAS G12D inhibitor, in MTAP-deleted, KRAS G12D-mutant pancreatic ductal adenocarcinoma (IDEAYA Biosciences Press Release) - "Genentech will sponsor the clinical combination study, and IDEAYA will supply IDE892...IDEAYA also plans to initiate a Phase 1 combination cohort with Roche's RG6505 in MTAP-deleted, RAS-mutant PDAC in 2H 2026....Under the clinical collaboration, IDEAYA and Genentech each retain all commercial rights to their respective compounds, including as monotherapy and as combination therapies. There will be joint governance to oversee the clinical supply collaboration."

Licensing / partnership • New P1 trial • Pancreatic Ductal Adenocarcinoma

In May, IDEAYA entered into a clinical trial collaboration with Roche to explore IDE892 in combination with RG6505, Roche's proprietary Phase 1 pan-RAS inhibitor, in MTAP-deleted, RAS-mutant PDAC to target the genetic co-alterations of MTAP and KRAS in this indication. (PRNewswire) - "IDEAYA plans to begin a Phase 1 combination trial in the second half of 2026. Upon joint IDEAYA and Roche approval, the collaboration may also evaluate a combination triplet with IDE892, RG6505, and IDE397, IDEAYA's proprietary Phase 1/2 MAT2A inhibitor."

Licensing / partnership • New P1 trial • Pancreatic Ductal Adenocarcinoma

Monotherapy expansion has been initiated in the Phase 1/2 clinical trial evaluating IDE892 in MTAP-deleted solid tumors, with a focus on non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC). (PRNewswire) - "The expansion has been initiated at projected efficacious target human exposures where 24-hour target EC90 coverage has been achieved. The IDE892 maximum tolerated dose (MTD) has not yet been reached in the ongoing dose escalation."

Trial status • Non Small Cell Lung Cancer • Pancreatic Ductal Adenocarcinoma

A Phase 1/2 combination cohort was initiated to evaluate IDE892 with IDE397, IDEAYA's proprietary MAT2A inhibitor, in MTAP-deleted cancers. (PRNewswire) - "Expansion is planned by year end 2026 or early 2027, with an initial clinical focus on MTAP-deleted NSCLC."

Trial status • Non Small Cell Lung Cancer

IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers (PRNewswire) - "IDE892 monotherapy Phase 1 escalation has cleared multiple dose cohorts with maximally efficacious target exposures anticipated at a favorable pill size and the MTD has not yet been reached. IDE892 monotherapy expansion is anticipated in Q3 2026...Next, IDEAYA is advancing a third proprietary program for MTAP-deleted solid tumors targeting CDKN2A, the most common co-alteration of MTAP, through ongoing preclinical toxicology studies to support an investigational new drug (IND) application in the first half of 2027."

IND • Trial status • Non Small Cell Lung Cancer • Pancreatic Cancer

IDE892 as monotherapy and in combination with IDE397 in patients with 5-methylthioadenosine phosphorylase-deleted (MTAP-Del) advanced solid tumors (IDE892001): Phase 1 trial. (ASCO 2026) - P1 | "Exploratory assessments include progression free survival, changes in circulating and tumor‑based markers of PRMT5 pathway modulation, molecular predictors of response, exposure–response relationships, and metabolite characterization. Clinical trial information: NCT07277413."

Clinical • Combination therapy • Metastases • Monotherapy • P1 data • Biliary Cancer • Biliary Tract Cancer • Gastrointestinal Cancer • Heart Failure • Infectious Disease • Lung Cancer • Mesothelioma • Non Small Cell Lung Cancer • Oncology • Solid Tumor • MAT2A • MTAP

IDE892 (PRMT5):…IDEAYA is planning to initiate a Phase 1 combination cohort with IDE397, its proprietary MAT2A inhibitor, in MTAP-deleted cancers in mid-2026 and expansion in the second half of 2026. (IDEAYA Biosciences Press Release) - "Dual inhibition of IDE892 and IDE397 has demonstrated durable and well-tolerated tumor regressions in preclinical MTAP-deleted tumor models, including in NSCLC."

New trial • Preclinical • Solid Tumor

IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deleted Solid Tumors, and Provides MTAP and CDKN2A Pipeline Update (PRNewswire) - "IDE892 is being evaluated as a monotherapy agent in MTAP-deleted solid tumors, including NSCLC and PDAC, and targeting combination FPI with IDE397 (MAT2A) in mid-2026; Targeting nomination of a first-in-class CDKN2A development candidate in H2 2026 and IND in H1 2027; prevalence of CDKN2A-deficiency has been reported at over 80% in PDAC; IDEAYA will deprioritize combination activities with Trodelvy as part of a strategic prioritization of its proprietary MTAP-deleted and CDKN2A pipeline."

IND • Pipeline update • Trial status • Non Small Cell Lung Cancer • Pancreatic Ductal Adenocarcinoma

IDE892 is a highly potent and selective PRMT5 inhibitor, with MTA-positive and SAM-negative cooperativity, optimized for development in MTAPdel cancers in combination with the allosteric MAT2A inhibitor IDE397 (AACR 2026) - "Whole transcriptome, proteome, and mRNA/tRNA methylome analyses indicated both shared and distinct contributions of IDE397 and IDE892 to perturbation of MTAPdel cellular systems which translated to robust combination benefit in MTAPdel CDX and PDX models. These preclinical studies indicate that the combination of IDE892/IDE397 has the potential to deliver durable therapeutic activity for patients harboring MTAPdel tumors; an opportunity that is currently under evaluation in phase 1 clinical trials."

Combination therapy • Oncology • CDKN2A • MAT2A • MTAP

IDEAYA Biosciences Announces Upcoming Presentations at AACR 2026 Highlighting Multiple Clinical Stage Pipeline Programs (PRNewswire) - "The presentations will highlight preclinical data from three potential first-in-class programs from IDEAYA's clinical stage pipeline: IDE034, a PTK7/B7H3 bi-specific topoisomerase-1 (TOP1) antibody-drug conjugate (ADC); IDE574, a potent dual inhibitor of the lysine acetyltransferase (KAT) 6 and 7; and IDE892, an MTA-cooperative inhibitor of PRMT5."

Preclinical • Oncology

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=260 | Recruiting | Sponsor: IDEAYA Biosciences | Not yet recruiting ➔ Recruiting

Enrollment open • Monotherapy • Bladder Cancer • Esophageal Adenocarcinoma • Esophageal Cancer • Gastric Adenocarcinoma • Gastric Cancer • Gastroesophageal Cancer • Genito-urinary Cancer • Lung Adenocarcinoma • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Malignant Pleural Mesothelioma • Mesothelioma • Non Small Cell Lung Cancer • Oncology • Peritoneal Mesothelioma • Pleural Mesothelioma • Solid Tumor • Urothelial Cancer • MTAP

2026 Corporate Objectives:…MTAP Pathway (PRNewswire) - "(i) IDE397 (MAT2A): provide updated data from Phase 1/2 combination trial with Trodelvy in MTAP-deleted urothelial cancer (UC) at a medical conference in 2026; (ii) IDE892 (PRMT5): initiate a Phase 1 monotherapy dose escalation trial in Q1 '26 to enable a combination trial with IDE397 in MTAP-deleted non-small cell lung cancer (NSCLC) in Q2 '26; (iii) Submit an investigational new drug (IND) application for a potential first-in-class program targeting CDKN2A, the most common co-alteration of MTAP, by the end of 2026."

IND • New P1 trial • P1/2 data • Non Small Cell Lung Cancer • Urothelial Cancer

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=260 | Not yet recruiting | Sponsor: IDEAYA Biosciences

Monotherapy • New P1 trial • Bladder Cancer • Esophageal Adenocarcinoma • Esophageal Cancer • Gastric Adenocarcinoma • Gastric Cancer • Gastroesophageal Cancer • Genito-urinary Cancer • Lung Adenocarcinoma • Lung Cancer • Malignant Pleural Mesothelioma • Mesothelioma • Non Small Cell Lung Cancer • Oncology • Peritoneal Mesothelioma • Pleural Mesothelioma • Solid Tumor • Urothelial Cancer

IDEAYA Biosciences Announces IND Submission for IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deletion Solid Tumors (PRNewswire) - "The company is targeting to begin a Phase 1 dose escalation trial of IDE892 in MTAP-deleted lung cancer in the fourth quarter of 2025, with the goal of advancing into combination trials with IDE397...in the first half of 2026....Preclinical profile of IDE892 and mechanistic combination rationale with IDE397...inhibitor, will be presented at the 10-Year Anniversary R&D Day on September 8th."

IND • New P1 trial • Preclinical • Solid Tumor

IDEAYA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update (PRNewswire) - "IDE892: a potential best-in-class MTA-cooperative PRMT5 inhibitor to enable wholly-owned combination with IDE397. IND filing targeted for mid-year 2025....IDE034: a potential first-in-class B7H3/PTK7 TOP1i bispecific ADC with combination potential with IDE161. IND filing targeted for the second half of 2025. IDE574: a potential first-in-class KAT6/7 dual inhibitor development candidate with combination opportunities with multiple programs in the Company's pipeline. IND filing targeted for the second half of 2025."

IND • Oncology

IDEAYA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update (PRNewswire) - "IDEAYA plans to enable the wholly-owned IDE397 and IDE892 (PRMT5MTA) combination in patients with MTAP-deletion non-small cell lung cancer (NSCLC) in the second half of 2025....Initiation of evaluation of IDE849 and IDE161 combination targeted in the second half of 2025....Targeting to present preclinical combination mechanism and synergy efficacy data of IDE161 with TOP1-payload based ADCs at a medical conference in the third quarter of 2025."

New trial • Preclinical • Non Small Cell Lung Cancer

IDEAYA Biosciences Announces Phase 1/2 Expansion for IDE397 and Trodelvy Combination in MTAP-Deletion Urothelial Cancer (PRNewswire) - "IDEAYA Biosciences...announced the initiation of a Phase 1/2 expansion in the clinical trial evaluating IDE397, its investigational, potential first-in-class, small molecule methionine adenosyltransferase 2a (MAT2A) inhibitor, in combination with Gilead's Trodelvy (sacituzumab govitecan-hziy), a Trop-2 directed antibody-drug conjugate (ADC), in methylthioadenosine phosphorylase (MTAP)-deletion urothelial cancer (UC) based on preliminary safety and clinical efficacy data....A clinical program update on the IDE397 and Trodelvy combination is planned in 2025. In addition to the clinical trial program evaluating IDE397 in combination with Trodelvy, IDEAYA is has a monotherapy expansion study in MTAP-deletion NSCLC and UC and is expecting to initiate a wholly-owned clinical combination trial of IDE397 and IDE892, IDEAYA's potential best-in-class, MTA-cooperative PRMT5 inhibitor in the second half of 2025."

New P1/2 trial • New trial • Non Small Cell Lung Cancer • Urothelial Cancer

IDEAYA Announces Further Gilead Sciences Clinical Study Collaboration Evaluating Combination of Trodelvy and IDE397 in MTAP-Deletion NSCLC (PRNewswire) - "IDEAYA Biosciences...announced it has entered into an additional clinical study collaboration and supply agreement with Gilead Sciences, Inc...to evaluate the efficacy and safety of IDE397, its investigational, potential first-in-class, small molecule MAT2A inhibitor, in combination with Gilead's Trodelvy (sacituzumab govitecan-hziy), a Trop-2 directed antibody-drug conjugate (ADC), in methylthioadenosine phosphorylase (MTAP)-deletion non-small cell lung cancer (NSCLC)...'look forward to providing clinical program updates in 2025,'...In addition to the Phase 1/2 trial evaluating IDE397 in combination with Trodelvy in UC and NSCLC, IDEAYA is actively enrolling patients into a monotherapy expansion in MTAP-deletion NSCLC and urothelial cancer and is expecting to initiate a wholly-owned clinical combination trial of IDE397 and IDE892, IDEAYA's potential best-in-class, MTA-cooperative PRMT5 inhibitor in the second half of 2025."

Commercial • New trial • Trial status • Non Small Cell Lung Cancer • Urothelial Cancer

IDEAYA Biosciences Announces Participation at the 43rd Annual J.P. Morgan Healthcare Conference and 2025 Corporate Guidance (PRNewswire) - "3 IND-filings targeted in 2025, representing IDEAYA's 7th, 8th, and 9th potential clinical stage precision medicine oncology program targeting solid tumors; IDE892, a potential best-in-class MTA-cooperative PRMT5 inhibitor, in mid-year 2025. Combination potential with IDE397; IDE034, a potential first-in-class B7H3/PTK7 TOP1i bispecific ADC, in the second half of 2025. Combination potential with IDE161; IDE251, a potential first-in-class KAT6/7 dual inhibitor development candidate, in the second half of 2025. Combination potential with multiple programs in IDEAYA's pipeline..."

IND • Solid Tumor

IDEAYA Announces Agenda for Investor R&D Day Webcast on December 16, 2024 (PRNewswire) - "The presentations by IDEAYA management and key opinion leaders will showcase scientific insights and clinical development opportunities across IDEAYA's precision medicine oncology pipeline. In addition, IDEAYA will highlight its next-generation precision medicine pipeline programs, including IDE275 / GSK959, a potential first-in-class and best-in-class Phase 1 Werner Helicase inhibitor, IDE892, a potential best-in-class MTA-cooperative PMRT5 inhibitor, IDE034, a potential first-in-class B7H3/PTK7 topo-I-payload bispecific antibody drug conjugate (BsADC), and a potential first-in-class lysine acetyltransferase 6/7 (KAT6/7) development candidate."

Clinical • Oncology • Solid Tumor

IDEAYA Biosciences Announces Development Candidate Nomination of IDE892, a Potential Best-in-Class MTA-cooperative PRMT5 Inhibitor (PRNewswire) - "IDE892 was discovered through IDEAYA's iterative physics-based ligand design and optimization platform, and is a highly potent and selective MTA-cooperative PRMT5 inhibitor with best-in-class potential and favorable drug-like properties. IDE892 has demonstrated exceptionally selective antiproliferative activity in MTAP-deleted tumor cell models and durable complete responses in combination with MAT2A inhibitor IDE397 in challenging MTAP-deletion preclinical models. IND-enabling studies for IDE892 are ongoing to support an Investigational New Drug (IND) filing to the U.S. Food and Drug Administration (FDA) in mid-2025, subject to satisfactory completion of ongoing preclinical and IND-enabling studies."

IND • New molecule • Oncology